These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7373309)

  • 1. Extension of the labeled precursor method of measuring neurotransmitter kinetics to non-steady-state conditions: application to striatal dopamine metabolism.
    Paden CM; Young SJ; MacGregor RJ
    J Neurochem; 1980 May; 34(5):1296-303. PubMed ID: 7373309
    [No Abstract]   [Full Text] [Related]  

  • 2. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 3. Substantia nigra and pentylenetetrazol threshold in rats: correlation with striatal dopamine metabolism.
    Fariello RG; Hornykiewicz O
    Exp Neurol; 1979 Jul; 65(1):202-8. PubMed ID: 262229
    [No Abstract]   [Full Text] [Related]  

  • 4. Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway.
    Oberlander C; Euvrard C; Dumont C; Boissier JR
    Eur J Pharmacol; 1979 Dec; 60(2-3):163-70. PubMed ID: 575095
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of electrical stimulation of the nigrostriatal pathway of the rat on dopamine metabolism.
    Korf J; Grasdijk L; Westerink BH
    J Neurochem; 1976 Mar; 26(3):579-84. PubMed ID: 1262880
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of the dendritic release of dopamine in the reciprocal control of the two nigro-striatal dopaminergic pathways.
    Leviel V; Chéramy A; Glowinski J
    Nature; 1979 Jul; 280(5719):236-9. PubMed ID: 450141
    [No Abstract]   [Full Text] [Related]  

  • 7. Stimulation of the subthalamic nucleus enhances the release of dopamine in the rat substantia nigra.
    Mintz I; Hammond C; Guibert B; Leviel V
    Brain Res; 1986 Jun; 376(2):406-8. PubMed ID: 3730844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms contributing to the recovery of striatal releasable dopamine following MFB stimulation.
    Michael AC; Ikeda M; Justice JB
    Brain Res; 1987 Sep; 421(1-2):325-35. PubMed ID: 3500755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine released from dendrites in the substantia nigra controls the nigral and striatal release of serotonin.
    Hery F; Soubrie P; Bourgoin S; Motastruc JL; Artaud F; Glowinski J
    Brain Res; 1980 Jul; 193(1):143-51. PubMed ID: 6247027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-o-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway.
    Reches A; Mielke LR; Fahn S
    Neurology; 1982 Aug; 32(8):887-8. PubMed ID: 7201586
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of blocking dopamine release on synthesis rate of dopamine in the striatum of the rat.
    Van Zwieten-Boot BJ; Noach EL
    Eur J Pharmacol; 1975; 33(2):247-54. PubMed ID: 171162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative histochemical studies of striatal dopamine depletion following DL-alpha-methyl-p-tyrosine administration.
    Dowson JH
    Neuropharmacology; 1973 Oct; 12(10):949-53. PubMed ID: 4750563
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemical or electrolytic lesion of the substantia nigra: early effects on neostriatal dopamine metabolism.
    Agid Y; Javoy F; Glowimski J
    Brain Res; 1974 Jul; 74(1):41-9. PubMed ID: 4847602
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitory influence of the nigrostriatal dopamine system on the striatal cholinergic neurons in the rat.
    Agid Y; Guyenet P; Glowinski J; Beaujouan JC; Javoy F
    Brain Res; 1975 Mar; 86(3):488-92. PubMed ID: 1116013
    [No Abstract]   [Full Text] [Related]  

  • 16. On the role of ascending catecholaminergic projections in intracranial self-stimulation of the substantia nigra.
    Clavier RM; Fibiger HC
    Brain Res; 1977 Aug; 131(2):271-86. PubMed ID: 890458
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of dopaminergic influence on striatal-nigral neurotensin systems.
    Letter AA; Matsuda LA; Merchant KM; Gibb JW; Hanson GR
    Brain Res; 1987 Sep; 422(1):200-3. PubMed ID: 3119151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axonal transport of proteins and glycoproteins in the rat nigro-striatal pathway and the effects of 6-hydroxydopamine.
    Roger LJ; Breese GR; Morell P
    Brain Res; 1980 Sep; 197(1):95-112. PubMed ID: 6156743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: lesion studies.
    Pollard H; Llorens C; Schwartz JC; Gros C; Dray F
    Brain Res; 1978 Aug; 151(2):392-8. PubMed ID: 209865
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological analysis of the functional ontogeny of the nigrostriatal dopaminergic neurons.
    Cheronis JC; Erinoff L; Heller A; Hoffmann PC
    Brain Res; 1979 Jun; 169(3):545-60. PubMed ID: 36209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.